GlassScriptPhysician profile
Steven G Clark
NPI 1053408476
$5,103.30
in general payments reported to CMS, 2019-2025
33 companies · $857 in 2025
The $857 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,713 · 2020: $602 · 2021: $791 · 2022: $405 · 2023: $311 · 2024: $424 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,592.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,193.11 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Astrazeneca Pharmaceuticals LP | $849.89 | 2019-2025 | Airsupra, Farxiga |
| Pfizer INC. | $356.85 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $314.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $296.48 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.25 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $219.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $197.74 | 2021-2025 | |
| Mylan Specialty L.P. | $193.83 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.84 | 2022-2024 | |
| Amgen INC. | $168.28 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $115.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $84.80 | 2019-2021 | |
| Amarin Pharma, INC. | $77.24 | 2020-2021 | |
| Alpha Cognition USA, INC. | $67.69 | 2025 | Zunveyl |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $66.02 | 2019-2025 | Veozah |
| Dexcom, INC. | $54.91 | 2021-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $53.19 | 2019-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $45.03 | 2019-2021 | |
| Eisai INC. | $44.59 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.73 | 2019-2021 | |
| Lundbeck LLC | $33.78 | 2025 | Rexulti |
| Ardelyx, INC. | $27.91 | 2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $26.12 | 2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $25.52 | 2020-2022 | |
| Abbott Laboratories | $24.47 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.07 | 2021 | |
| Corium, LLC | $19.94 | 2022 | |
| Smith+Nephew, INC. | $14.53 | 2019 | |
| Breas Medical, INC. | $13.63 | 2024 | Vivo 45 Ls |
| Esperion Therapeutics, INC. | $13.60 | 2025 | Nexletol |
| Sanofi Pasteur INC. | $13.24 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.